Effect of COX-1/COX-2 Inhibition versus Selective COX-2 Inhibition on Coronary Vasodilator Responses to Arachidonic Acid and Acetylcholine

  title={Effect of COX-1/COX-2 Inhibition versus Selective COX-2 Inhibition on Coronary Vasodilator Responses to Arachidonic Acid and Acetylcholine},
  author={Garrett John Gross and Jeannine M Moore},
  pages={135 - 142}
The effect of a nonselective COX-1/COX-2 inhibitor, naproxen, was compared with a COX-2-selective inhibitor (SC-58236) on coronary vasodilatory responses in the anesthetized dog. Coronary vasodilation was induced by direct intracoronary injection of acetylcholine (ACH) and arachidonic acid (AA) in control animals and in those treated with either naproxen (1, 3, or 10 mg/kg p.o. 24 h prior to the experiment) or SC-58236 (1, 5, or 15 mg/kg p.o. 24 h prior to the experiment). Naproxen, at 10 mg/kg… 

Figures and Tables from this paper

Effects of cyclooxygenase inhibition on canine coronary artery blood flow and thrombosis.
The data suggest that AA-induced vasodilatation in the normal coronary artery is mediated by a single COX isoform, the constitutive endothelial COX-1, which is reported to be susceptible toCOX-2 inhibitors, thereby suggesting that the endothelial constitutive COZ-1 and the inducible vascular COx-2 serve important functions in maintaining vascular homeostasis.
Pathophysiology of Cyclooxygenases in Cardiovascular Homeostasis
This article focuses on the expression and function of COX enzymes in normal and pathologic conditions of the cardiovascular system and discusses the cardiovascular pathophysiologic complications associated with COX inhibition.
Cyclooxygenase-1 or -2--which one mediates lipopolysaccharide-induced hypothermia?
It is concluded that COX-1, but notCOX-2, mediates LPS hypothermia, and that both COX isoforms are required for LPS hypotension.
Cardiovascular complications of non-steroidal anti-inflammatory drugs.
  • E. Fosslien
  • Medicine, Biology
    Annals of clinical and laboratory science
  • 2005
In conclusion, to reduce the risk of cardiovascular complications during long-term coxib therapy, low-dose aspirin supplementation should be considered and an alternative is to use a less COX-2-selective inhibitor such as meloxicam.
Review : Cardiovascular Complications of Non-Steroidal Anti-Inflammatory Drugs
To reduce the risk of cardiovascular complications during long-term coxib therapy, low-dose aspirin supplementation should be considered and an alternative is to use a less COX-2-selective inhibitor such as meloxicam.
Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
  • E. Dajani, K. Islam
  • Medicine
    Journal of physiology and pharmacology : an official journal of the Polish Physiological Society
  • 2008
Additional comprehensive, long-term, prospective investigations comparing the CV and GI safety profile of marketed NSAIDs against each other and against selective inhibitors are needed to address the controversy of COX inhibitors.
Molecular Mechanisms Regulating the Vascular Prostacyclin Pathways and Their Adaptation during Pregnancy and in the Newborn
Careful examination of PGI2 metabolism and the complex interplay with other prostanoids will help design specific modulators of the P GI2-dependent pathways for the management of pregnancy-related and neonatal vascular disorders.
Cardio-renal safety of non-steroidal anti-inflammatory drugs.
This review summarizes major learnings on cardiac and renal complications associated with pharmaceutical inhibition of COX-1 andCOX-2 with focus on preclinical to clinical translatability of cardio-renal data.


Effects of Selective Cyclooxygenase-2 Inhibition on Vascular Responses and Thrombosis in Canine Coronary Arteries
The results indicate important physiological roles for COX-2–derived prostacyclin and raise concerns regarding an increased risk of acute vascular events in patients receiving COx-2 inhibitors, which may be increased in individuals with underlying inflammatory disorders.
Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2.
Prostaglandins (PG) are synthesized by two isoforms of the enzyme PG G/H synthase [cyclooxygenase (COX)]. To examine selectivity of tolerated doses of an inhibitor of the inducible COX-2 in humans,
Inhibition of cyclooxygenase-2 rapidly reverses inflammatory hyperalgesia and prostaglandin E2 production.
It is suggested that continuous production of PGE2 by the COX-2 enzyme is a critical element in sustaining the hyperalgesic response at sites of tissue inflammation.
Effects of Celecoxib, a Novel Cyclooxygenase‐2 Inhibitor, on Platelet Function in Healthy Adults: A Randomized, Controlled Trial
The results indicate that even at supratherapeutic doses, celecoxib will not interfere with normal mechanisms of platelet aggregation and hemostasis, supporting the premise that cele Coxib is COX‐1 sparing relative to conventional NSAIDs.
Selective COX-2 Inhibition Improves Endothelial Function in Coronary Artery Disease
This is the first study to demonstrate that selective COX-2 inhibition improves endothelium-dependent vasodilation and reduces low-grade chronic inflammation and oxidative stress in coronary artery disease and holds the potential to beneficially impact outcome in patients with cardiovascular disease.
Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor: efficacy and safety in two placebo-controlled trials in osteoarthritis and rheumatoid arthritis, and studies of gastrointestinal and platelet effects.
SC-58635 achieves analgesic and antiinflammatory efficacy in arthritis through selectiveCOX-2 inhibition, without showing any evidence of 2 of the toxic effects of COX-1 inhibition associated with nonsteroidal antiinflammatory drugs.
Effect of selective cyclooxygenase 2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly.
The findings of this observational study suggest no increase in the short-term risk of AMI among users of selective cyclooxygenase 2 inhibitors as commonly used in clinical practice and do not support a short- term reduced risk ofAMI with naproxen.
Cyclooxygenase 2—implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspectives
Observations that expression of COX-2 mRNA and protein is upregulated at the ulcer margin in a temporal and spatial relation to enhanced epithelial cell proliferation and increased expression of growth factors support the concept that COx-2 represents a further line of defence for the gastrointestinal mucosa necessary for maintenance of mucosal integrity and ulcer healing.
Efficacy Assessment of Meloxicam, a Preferential Cyclooxygenase-2 Inhibitor, in Acute Coronary Syndromes Without ST-Segment Elevation: The Nonsteroidal Anti-Inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) Pilot Study
Meloxicam with heparin and aspirin was associated with significant reductions in adverse outcomes in acute coronary syndrome patients without ST-segment elevation and additional larger trials are required to confirm the findings.